Pfizer (NYSE:PFE) hit its peak during the COVID-19 pandemic when its vaccines developed with BioNTech SE (NASDAQ:BNTX) sent shares surging up to $61.71 in December 2021, driven by its COVID-19 vaccine sales.
Recent Mentions
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
•
•
•
•
•
•
•
•
Country
DE
Industry
Health Care
Market Cap
Large Cap
Num. Employees
6133
IPO Date
Oct 10, 2019
Country
DE
Industry
Health Care
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. The company is headquartered in Mainz, Rheinland-Pfalz and currently employs 6,133 full-time employees. The company went IPO on 2019-10-10. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The firm is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Sources
Mentions
Mentions of this stock across all news source scraped in the past 30 days
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
Finnhub
27.78%
globenewswire.com
11.11%
Yahoo
11.11%
Others
50%
News Sentiment
Sentiment
Composite sentiment (positive vs. negative language) expressed across news sources mentioning this stock
Today
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
Neutral
Related Stocks
Related Stocks
Stocks being mentioned with BNTX